To many scientists, it may seem that HIV prevention research has succeeded – large clinical trials of oral pre-exposure prophylaxis (PrEP) and vaginal formulations of antiretroviral drugs (ARVs) demonstrated that these products can indeed prevent HIV infection when used [1-3]. This is great news!
But the problem we face as a global HIV prevention community is not whether or not we have efficacious products. The problem is whether or not the products will appropriately meet women’s needs and lifestyles and thus whether or not women will use them. Adherence to product use is quite possibly the biggest issue blocking the eradication of sexual HIV transmission .